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Abstract
Background and aims: Cerebrovascular accidents [CVA] have rarely been reported in inflammatory 
bowel disease [IBD] patients treated with anti-tumour necrosis alpha [anti-TNF alpha] agents. Our 
aim here was to describe the clinical course of CVA in these patients.
Methods: This was a European Crohn’s and Colitis Organisation [ECCO] retrospective observational 
study, performed as part of the CONFER [COllaborative Network For Exceptionally Rare case 
reports] project. A call to all ECCO members was made to report on IBD patients afflicted with CVA 
during treatment with anti-TNF alpha agents. Clinical data were recorded in a standardised case 
report form and analysed for event association with anti-TNF alpha treatment.
Results: A total of 19 patients were identified from 16 centres: 14 had Crohn’s disease, four 
ulcerative colitis and one IBD colitis unclassified [median age at diagnosis: 38.0  years, range: 
18.6–62.5]. Patients received anti-TNF alpha for a median duration of 11.8 months [range: 0–62] 
at CVA onset; seven had previously been treated with at least one other anti-TNF alpha agent. 
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Complete neurological recovery was observed in 16 patients. Anti-TNF alpha was discontinued in 
16/19 patients. However, recurrent CVA or neurological deterioration was not observed in any of 
the 11 patients who received anti-TNF alpha after CVA [eight resumed after temporary cessation, 
three continued without interruption] for a median follow-up of 39.8 months [range: 5.6–98.2].
Conclusion: These preliminary findings do not unequivocally indicate a causal role of anti-TNF 
alpha in CVA complicating IBD. Resuming or continuing anti-TNF alpha in IBD patients with CVA 
may be feasible and safe in selected cases, but careful weighing of IBD activity versus neurological 
status is prudent.
Keywords:  Cerebrovascular accidents; inflammatory bowel disease; anti-TNF alpha agents
1. Introduction
Inflammatory bowel disease [IBD] is considered an independent risk 
factor for thrombosis. Prevalence of thromboembolic events [arterial 
or venous thrombosis] in IBD is reported between 1.3–6.0%, with 
a 1.5–3.6-fold increased risk compared with the general popula-
tion and other inflammatory disorders.1,2,3 This risk reaches 15-fold 
when referring to active IBD.4 Cerebrovascular accidents [CVA] are 
infrequently reported in IBD patients, mostly in the form of a single 
case report or small series5,6,7,8,9 with a reported overall prevalence 
of 0.12–4%.2
Anti-tumour necrosis factor alpha [anti-TNF alpha] agents revo-
lutionised IBD treatment. Infliximab and adalimumab are globally 
approved for the treatment of moderate to severe IBD.10 However, 
their long-term use has been associated with several neurological 
complications, primarily demyelinating and septic disorders.11,12 The 
association, if any, of anti-TNF alpha with CVA is hitherto unknown. 
This knowledge gap hampers the ability for rational decision mak-
ing in patients who develop or are at risk of developing CVA while 
receiving anti-TNF alpha treatment.
We therefore set out to describe a series of IBD patients present-
ing with a CVA during anti-TNF alpha treatment, and to try to eluci-
date the impact of anti-TNF alpha resumption in these cases.
2. Materials and Methods
2.1. Study design
This European Crohn’s and Colitis Organisation [ECCO] obser-
vational multicentre study retrospectively collected cases across 
the world through the CONFER [COllaborative Network For 
Exceptionally Rare case reports] project. The CONFER project 
was initiated by ECCO in order to specifically identify and report 
together rare IBD disease associations, which otherwise seldom 
get reported due to their exceptional rarity. Briefly, the CONFER 
methodology comprised selecting a topic worthy of investigation 
out of case proposals submitted by ECCO members. Once a spe-
cific IBD disease association was selected by a steering committee 
as a CONFER project [CVA in IBD patients under antiTNF alpha 
therapy in the case of the present manuscript], ECCO launched a call 
to identify similar cases encountered by IBD physicians worldwide.
The call to physicians was made through announcements in the 
ECCO annual congress and in national IBD meetings across Europe 
and during two international IBD meetings [the Falk symposium in 
London 2013 and the Ferring symposium in Prague 2013]. In addi-
tion, the call for similar cases was disseminated by direct emails to 
all ECCO members and affiliated physicians and in the ECCO web-
site and eNews. Physicians were then prompted to report their case 
to the CONFER database using a pre-determined standardised case 
report form (CRF). The call for the present case series was entitled 
‘Have you encountered a case of CVA in an IBD patient associated 
or not with anti-TNF alpha therapy?’
2.2. Patients and procedures
Adult IBD patients having a CVA while receiving anti-TNF alpha 
therapy were eligible for inclusion in this study. Data were col-
lected by a CRF, which was divided into two main sections. Section 
1 included patient [epidemiological data, past history] and disease 
(date and summary of IBD diagnosis, Montreal classification, pres-
ence and summary of extra-intestinal manifestations, anti-neutrophil 
cytoplasmic antibody [ANCA] or anti-Saccharomyces cerevisiae 
antibody [ASCA] positivity, prior IBD treatment with particular 
interest in duration and reason for discontinuation, and prior sur-
gery for IBD) characteristics.
Section 2 was dedicated to description of the event. Symptoms and 
findings of the neurological examination were registered, including level 
of consciousness, speech abnormalities, visual fields defects, oculomotor 
disorders, abnormalities in the rest of the cranial nerves, muscle tone/
strength change, presence of pyramidal or extrapyramidal signs, sensory 
abnormalities, signs of cerebellar deficits, gait changes, asymmetrical 
tendon reflexes, and urinary and/or fecal incontinence. Relevant labora-
tory tests as well as appropriate imaging and clinical work-up [includ-
ing neuroradiological interventions] were also recorded.
CVA was defined as any ischaemic [thrombotic or embolic] or 
haemorrhagic [subarachnoid or intracerebral] stroke or any transient 
ischaemic attack.13 CVA was judged as mild, moderate, or severe 
according to the consulting neurologist’s decision. Event outcome was 
addressed at the time of report as ongoing or as having had a com-
plete, minor, or major recovery, fatal outcome or an unknown course, 
again based on the neurologist’s consultation. Special interest was 
given to whether anti-TNF alpha therapy was discontinued due to the 
event and whether it was re-introduced later on. Finally, a relationship 
between the CVA and the above-mentioned IBD regimens or other 
concomitant medication or comorbidities was investigated as impos-
sible, possible, or probable, as per the treating physician’s judgment.
All statistical analyses [frequencies, descriptive statistics, Shapiro–Wilk 
for normality and chi-square, Mann–Whitney test, and t-test for group com-
parison] were done with SPSS 20.0 software package [IBM SPSS Statistics, 
Armonk, NY, USA]. A p-value < 0.05 was considered statistically significant.
3. Results
3.1. Patients’ background information
A total of 28 centres initially responded to our call. Eight CRFs were 
excluded either due to insufficient data [five] or not being compatible 
with a CVA [two] or reluctance of the patient to consent [one]. One 
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additional case was initially included but subsequently excluded dur-
ing follow-up because the treating neurologist had severe doubts on 
the occurrence of a transient ischaemic attack [TIA]. Finally, 19 cases 
from 16 medical centres across the world were reported. Patients’ 
epidemiological and IBD characteristics are shown in Table  1; 17 
patients were treated with at least one immunosuppressant [IMS] 
[either azathioprine/mercaptopurine or methotrexate] prior to CVA 
and all had received at least one course of corticosteroids since IBD 
diagnosis. The most common reason for IMS discontinuation was an 
adverse event in nine patients, whereas in five the treatment was still 
ongoing at the time of the event.
Regarding anti-TNF alpha therapy, eight patients were treated 
with infliximab only, four with adalimumab only, four with both 
agents, and three with certolizumab pegol as a third-line agent. At 
the onset of CVA, eight patients were receiving the anti-TNF alpha 
agent as monotherapy, six as combination therapy with corticoster-
oids, three as combination therapy with methotrexate, and two as 
triple combination therapy with corticosteroids and azathioprine. 
The duration of treatment until CVA onset was variable and aver-
aged 11.8 ± 16.6 months [median: 5.0, range: 0.0–62.0]. More spe-
cifically, 8/19 [42.1%] were receiving anti-TNF alpha for more than 
6 months before the CVA [Figure 1]. The mean [± SD] time inter-
val between last anti-TNF alpha dose and CVA was 23.6 [± 20.9] 
days for infliximab and 8.4 [± 4.9] days for adalimumab. Only five 
patients were under an intensified anti-TNF alpha regimen at the 
time of the event.
3.2. CVA characteristics and outcome
CVA characteristics for the 19 patients are shown in Table  2. 
Symptoms and signs were diverse, with 10/19 patients presenting 
with hemiparesis and seven with visual disturbances. Dysarthria, 
numbness, perioral paraesthesia, ataxia, headache, vomiting, coor-
dination deficits, loss of consciousness, grand mal epilepsy, and 
bilateral choreoathetoid movements were also reported. Complete 
blood count and C-reactive protein were normal in the majority of 
patients. Electrocardiography and Holter monitoring were normal 
in all patients who underwent these studies, whereas echocardiog-
raphy showed patent foramen ovale in three patients. Brain com-
puted tomographic or magnetic resonance imaging and angiography 
were either normal or demonstrated diverse findings [Table  2]. 
Coagulopathy tests conducted in 12 patients revealed factor V 
[Leiden] deficiency, hyperfibrinogenaemia, and hyperhomocysteinae-
mia in one patient each, whereas results were normal in nine.
CVA severity was judged as serious in 11 patients, moderate in 
three and mild in five. Recovery was complete in 16 patients, major 
in one and minor in two at last follow-up [Table 2].
IMS was discontinued in six and anti-TNF alpha was withheld 
in all but three patients due to the CVA. Anti-TNF alpha therapy 
was re-introduced at the regular dosing protocol after CVA resolu-
tion in six patients and at an intensified dosing schedule in two, and 
none of these patients experienced a new episode of CVA or neuro-
logical deterioration over a mean follow-up of 39.8 months [median: 
37.8, range: 5.6–98.2]. Anti-TNF alpha was not re-introduced in 
the remaining patients due to IBD remission in two, introduction 
of ustekinumab in one, methotrexate-induced clinical remission in 
one, colectomy in one, physician’s concern regarding new central 
nervous system symptoms in one, and vasculitis in two for whom 
the biological was suspected to be the triggering factor. Relationship 
between the occurrence of the CVA and the IMS was judged by the 
treating physician as impossible in 11 patients and as possible in five, 
and between the CVA and the anti-TNF alpha therapy as impossible 
in three, as possible in 11, and as probable in five. Finally, six par-
ticipants indicated a possible and two a probable relationship of the 
event with comorbidities.
4. Discussion
The present study describes a series of IBD patients affected by a CVA 
while being treated with an anti-TNF alpha agent. Twelve patients 
had received only one anti-TNF alpha agent at the time of the event, 
whereas seven had received at least one other anti-TNF alpha agent 
before the index one, without any prior CVA. The vast majority 
[17/19] were also treated with an IMS either simultaneously or prior 
to the event. Importantly, neurological recovery was complete in 
16 patients. Moreover, anti-TNF alpha was re-introduced in eight 
patients and continued un-interrupted in another three without any 
seeming consequence in the form of recurrent CVA or deterioration 
of neurological status. Notably, this is, to our knowledge, the largest 
Table 1. Demographic and clinical characteristics.
Characteristics Number
Female/male [n] 9/10
Caucasian [n] 19
Smokers/non-smokers/ex-smokers, n = 18 6/7/5
CD/UC/IBDU [n] 14/4/1
Extra-intestinal manifestations [n] 9
IBD activity at CVA: active/quiescent, n = 18 9/9
Familial IBD history [n] 4 [all CD]
CD: ileitis/colitis/ileocolitis/perianal, n= 14 3/0/11/5
CD: B1/B2andB3, n = 14 9/5
UC: E1/E2/E3, n = 4 0/1/3
Major IBD surgeries at registration, n = 19 6
Mean [± SD, median] age at IBD diagnosis [years] 38.0 [± 14.8, 36.5]
Mean [± SD, median] age at CVA onset [years] 47.0 [± 17.6, 48.4]
Mean [± SD, median] IBD duration at CVA onset [years] 9.4 [± 9.5, 6.0]
Mean [± SD, median] anti-TNF alpha therapy duration at CVA [months] 11.8 [± 16.6, 5.0]
Mean [± SD, median] time interval between last anti-TNF alpha dose andand CVA [days] 17.3 [± 17.7, 10.0]
CD, Crohn’s disease; UC, ulcerative colitis; IBDu, inflammatory bowel disease unclassified; CVA, cerebrovascular accident; SD, standard deviation; TNF, tumour 
necrosis factor.
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described series of IBD patients exhibiting a CVA while receiving 
anti-TNF alpha therapy.
Neurological complications in IBD patients are not infrequent 
but are poorly recognised and under-reported. CVA are even more 
rare, with cerebral infarction, TIA, and cerebral venous thrombosis 
being most frequently reported.14,15 IBD is reported as the lead-
ing underlying condition in 1–6% of cerebral venous thrombosis 
incidents, in many of these cases not temporally associated with 
an IBD flare.15 Vasculitis, carotid arterial thrombosis, or thrombo-
embolism, retinal branch artery occlusion, and paradoxical embo-
lism are also reported as underlying CVA causes.16 It is unclear 
whether arterial or venous infarcts are more prevalent. However, 
cerebral arterial thrombotic events were more common in a recent 
population-based study.17 Our patients exhibited both venous and 
arterial events.
A recent meta-analysis showed that IBD is associated with an 
increased, albeit small, risk of CVA (odds ratio [OR] 1.18; 95% 
confidence interval [CI] 1.09–1.27), especially among women [OR 
1.28; 95% CI 1.17–1.41] and in younger patients [< 40–50 years 
old].18 Another population-based nested case-control study observed 
an increased risk for ischaemic stroke in younger [< 50 years old; OR 
2.93; 95% CI 1.44–5.98] CD patients.19 Finally, Ha et al. showed 
that young [< 40 years old] women with IBD exhibited an increased 
risk for stroke (hazard ratio [HR] = 2.1, p = 0.04).20 Our patients 
were equally distributed among genders but manifested the CVA at 
a younger mean age [47 years] than the general population. Another 
population-based study indicated that a higher risk for cerebral arte-
rial thromboembolic disease was associated only with CD (incidence 
rate ratio [IRR] 1.32; 95% CI,] 1.05–1.66).21 This may seem to be in 
accordance with our group of patients, in whom the majority have 
had CD [14/19, 73.6%]. However, inference is impossible, as our 
patients were selected by anti-TNF alpha treatment, which is more 
commonly administered to CD patients.
Peripheral neuritis and demyelinating disorders [multiple sclero-
sis and optical neuritis] are the most frequently reported neurologi-
cal adverse events in patients receiving anti-TNF alpha treatment.22,23 
A Food and Drug Administration-supported study reported 772 dis-
tinct neurological adverse events secondary to anti-TNF alpha agent 
exposure over a 10-year period.24 However, the occurrence of CVA 
in IBD patients receiving anti-TNF alpha agents has been scantily 
studied and reported.
Our case series demonstrated that CVA do occur in this sub-
group of anti-TNF alpha-treated IBD patients, which warrants 
prompt recognition and evaluation, although the majority of our 
patients recovered without significant neurological sequelae. CVA 
occurred early after anti-TNF alpha initiation in some patients. 
However, this could reflect the CVA being temporally related to a 
more active phase of disease than to the introduction of the anti-
TNF alpha agent [Figure 1]. Moreover, in 7/19 of the patients, CVA 
occurred after neurologically uneventful treatment with one or two 
other anti-TNF alpha agents prior to the index agent. Taken together 
with the fact that IBD itself may predispose at least to some forms 
of CVA, and that a proportion of patients exhibited additional risk 
factors for a CVA [ie smoking], the present observations may argue 
against a causal relation between the anti-TNF alpha agent and the 
CVA. Moreover, these findings could indicate that anti-TNF alpha 
may be safely resumed or continued in such patients, which may be 
important for patients who are dependent on anti-TNF alpha for 
IBD control. Nonetheless, these contentions should be perceived pre-
liminarily and adopted with great caution, given the limited number 
of patients in this study, the retrospective nature of data collection, 
and the fact that the study was not designed to assess the incidence 
of CVA during anti-TNF alpha treatment compared with its inci-
dence without these agents, nor whether anti-TNF alpha treatment 
modifies stroke incidence or severity in IBD patients. Physicians must 
exhibit increased vigilance when confronted with the occurrence of 
a CVA in an IBD patient under anti-TNF alpha therapy, and should 
explore further therapeutic options on a strict case-by-case basis, 
also keeping in mind potential non-medical consequences of their 
decision.
It should be noted that the outcome of CVA in our anti-TNF 
alpha-treated IBD patients seems no worse than the outcome of 
CVA in IBD patients not treated by anti-TNF alpha, based purely 
on clinical and imaging assessment, as described recently in a review 
of published case reports.14 However, there are obvious methodo-
logical caveats limiting a direct comparison. Studies in patients with 
rheumatoid arthritis and plaque psoriasis have produced conflicting 
results, either favouring the occurrence of thromboembolic events 
during anti-TNF alpha therapy25 or concluding that there is no 
correlation.26,27 Moreover, although an increase in anti-cardiolipin 
antibodies and possible thrombogenicity of anti-TNF alpha therapy 
have been proposed,28 there are conflicting mechanistic data sug-
gesting a role for elevated TNF alpha levels in the brain during CVA 
as partly mediating the neuronal damage,28,29,30,31,32 thereby pos-
sibly suggesting that TNF alpha blockade may be beneficial dur-
ing CVA. Elevated TNF alpha is also present in the vast majority 
of IBD patients, especially when the disease is active, but half of 
our patients were in remission when the CVA occurred, implicat-
ing a weak correlation with IBD activity. However, in the absence 
of population-based studies, this postulation remains at present 
speculative.
The limitation of the CONFER methodology should be acknowl-
edged, as it relies on voluntary submission of cases by physicians 
responding to ECCO calls, which could introduce geographical and 
other selection biases. However, we believe this caveat is offset by the 
benefits of this methodology for identifying and reporting larger case 
series of extremely rare events, which are otherwise seldom reported 
other than in a single case-report format.
In conclusion, CVA affecting IBD patients treated with anti-
TNF alpha agents mandates early recognition, proper work-up and 
specialist treatment, despite the fact that the outcome seemed to be 
favourable in the majority of cases in the present study. Permanent 
cessation of anti-TNF alpha treatment may not be universally man-
datory, as continuation or resumption of the biological may be safely 
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Figure  1. Anti-TNF alpha therapy duration [months] until CVA occurrence 
[N = 19].
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practised in some patients. However, until further data are available, 
this needs to be a case-by-case decision after careful weighing of the 
neurological state as well as the disease activity and risk for IBD 
complications in the individual patient.
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